- Home
- News
News
Foundation Fournier-Majoie
Challenge 88 : 44 days of sport and solidarity to better treat cancer
With a touch of 88*, what sporting, fun, crazy challenge will you take up? Walk, run, swim, dance, or … and get your friends and family together to support our project "The cloak of invisibility"
ParticipateFoundation Fournier-Majoie
Les Voiles du Zoute, supporting the Fournier-Majoie Foundation- 29-09-2022
the very first edition was held, for the benefit of the Foundation. A day of sharing and meetings which culminated in a dinner during which a work by Christophe de Fierlant was offered for auction
PicturesFoundation Fournier-Majoie
“Coup d’Eclat” Gala Evening
On Sep 22, 270 Venture Philanthropists participated in the 2nd "Coup d'Eclat" ,We are very happy about it.this evening was a real Coup d'Eclat
PicturesFoundation Fournier-Majoie
Sotheby’s International Realty puts us in the spotlight
As a partner, the famous real estate agency shows its support for cancer research and praises the Foundation's 100% model
Read the articleLaureates
Precirix raises €80m in Series B
A major step to accelerate growth and develop their technology platform manufacturing precision radiopharmaceuticals based on llama derived antibodies
Read moreFoundation Fournier-Majoie
Tribute to Bernard Majoie
It is with deep sadness that we share the passing of Bernard Majoie, at the age of 82.
Read the articleLaureates
ADCs capable of carrying more drug, with more homogeneity
Thanks to their particular envelope, the ADCs developed by Mablink Bioscience offer a superior drug-antibody ratio (DAR) and demonstrate high stability (FR)
Read the articleFoundation Fournier-Majoie
An exclusive BANKSY evening and a creation by KOOL KOOR to support us
The Foundation privatised the BANKSY exhibition during which the artist KOOL KOOR created and offered two works to support our projects. The generous participants enabled us to raise €45,000
Read the articleFoundation Fournier-Majoie
A promising new project in targeted cancer therapies
The Foundation Fournier-Majoie is contributing € 500,000 to the Mablink Bioscience project to build a new generation of ADCs, a class of drugs targeted against cancer (FR)
Read moreScience
Liquid biopsies for cutting-edge cancer medicine
The detection and characterization of circulating tumor DNA must be used in clinical practice, allowing accurate follow-up of cancer patients (FR)
Read the articleScience
Biomarkers clinical implications in colorectal metastatic cancer
How biomarkers could be used to improve personalised treatment regiments of metastatic colorectal cancer patients (mCRC) (NL)
Read the articleLaureates
DNAlytics wins the Digital Wallonia 4 Good Startup Award
Our 2017 laureate, a spinoff from UCLouvain, has been rewarded for its reactivity and solutions provided to the FPS Health in the context of the Covid-19 pandemic (FR)
Read the articleScience
Pesticides: meta-analysis points to responsibility for some blood cancers
Pesticide use has been correlated with acute myeloid leukemia (FR)
Read the articleScience
Colorectal cancer screening: “Don’t postpone your examination”
Colorectal cancer is the second leading cause of cancer death in Belgium. It is urgent for the over-50s to be screened, despite the Covid-19 pandemic (FR)
Read the articleLaureates
Plants to produce a new anti-cancer molecule
ATB Therapeutics (our 2017 laureat) has developed a platform capable of generating innovative molecules from plants to fight cancer. A promising fundraising (FR)
Read the articleScience
Artificial Intelligence produces specific, optimized CAR-T cells to target cancer cells in patients
AI technology is being used to produce highly potent and optimally adapted CAR-T cell products that target the altered cells in the patient's blood or the tumor (EN)
Read the articleScience
Sanofi prepares the future in auto-immune diseases and cancer
By acquiring Kymab, Sanofi is opening up a new research and development axis in the field of monoclonal antibodies (proteins protecting our bodies from foreign substances)
Read the articleLaureates
Precirix appoints Dr. Niva Almaula as Chief Business Officer
Precirix, a private biotech that clinically tests radiopharmaceuticals in oncology, announces the arrival of Dr. Niva Almaula who will lead the company's global development strategy
Read the article